Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 1
2006 2
2007 3
2008 6
2009 3
2010 3
2011 1
2012 3
2013 10
2014 4
2015 3
2017 2
2018 4
2019 6
2020 1
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

52 results
Results by year
Filters applied: . Clear all
Page 1
Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans.
Kaasinen E, Kuismin O, Rajamäki K, Ristolainen H, Aavikko M, Kondelin J, Saarinen S, Berta DG, Katainen R, Hirvonen EAM, Karhu A, Taira A, Tanskanen T, Alkodsi A, Taipale M, Morgunova E, Franssila K, Lehtonen R, Mäkinen M, Aittomäki K, Palotie A, Kurki MI, Pietiläinen O, Hilpert M, Saarentaus E, Niinimäki J, Junttila J, Kaikkonen K, Vahteristo P, Skoda RC, Seppänen MRJ, Eklund KK, Taipale J, Kilpivaara O, Aaltonen LA. Kaasinen E, et al. Among authors: kilpivaara o. Nat Commun. 2019 Mar 19;10(1):1252. doi: 10.1038/s41467-019-09198-7. Nat Commun. 2019. PMID: 30890702 Free PMC article.
ERCC6L2 defines a novel entity within inherited acute myeloid leukemia.
Douglas SPM, Siipola P, Kovanen PE, Pyörälä M, Kakko S, Savolainen ER, Salmenniemi U, Orte K, Kytölä S, Pitkänen E, Porkka K, Kilpivaara O, Wartiovaara-Kautto U. Douglas SPM, et al. Among authors: kilpivaara o. Blood. 2019 Jun 20;133(25):2724-2728. doi: 10.1182/blood-2019-01-896233. Epub 2019 Apr 1. Blood. 2019. PMID: 30936069 Free article. No abstract available.
CTCF/cohesin-binding sites are frequently mutated in cancer.
Katainen R, Dave K, Pitkänen E, Palin K, Kivioja T, Välimäki N, Gylfe AE, Ristolainen H, Hänninen UA, Cajuso T, Kondelin J, Tanskanen T, Mecklin JP, Järvinen H, Renkonen-Sinisalo L, Lepistö A, Kaasinen E, Kilpivaara O, Tuupanen S, Enge M, Taipale J, Aaltonen LA. Katainen R, et al. Among authors: kilpivaara o. Nat Genet. 2015 Jul;47(7):818-21. doi: 10.1038/ng.3335. Epub 2015 Jun 8. Nat Genet. 2015. PMID: 26053496
Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up.
Baliakas P, Tesi B, Wartiovaara-Kautto U, Stray-Pedersen A, Friis LS, Dybedal I, Hovland R, Jahnukainen K, Raaschou-Jensen K, Ljungman P, Rustad CF, Lautrup CK, Kilpivaara O, Kittang AO, Grønbæk K, Cammenga J, Hellström-Lindberg E, Andersen MK. Baliakas P, et al. Among authors: kilpivaara o. Hemasphere. 2019 Nov 4;3(6):e321. doi: 10.1097/HS9.0000000000000321. eCollection 2019 Dec. Hemasphere. 2019. PMID: 31976490 Free PMC article.
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.
Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL. Koppikar P, et al. Among authors: kilpivaara o. Nature. 2012 Sep 6;489(7414):155-9. doi: 10.1038/nature11303. Nature. 2012. PMID: 22820254 Free PMC article.
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.
Quintás-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S. Quintás-Cardama A, et al. Among authors: kilpivaara o. Blood. 2013 Aug 8;122(6):893-901. doi: 10.1182/blood-2012-07-442012. Epub 2013 Jun 19. Blood. 2013. PMID: 23782935 Free PMC article. Clinical Trial.
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL. Abdel-Wahab O, et al. Among authors: kilpivaara o. Blood. 2009 Jul 2;114(1):144-7. doi: 10.1182/blood-2009-03-210039. Epub 2009 May 6. Blood. 2009. PMID: 19420352 Free PMC article.
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.
Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel JP, Mermel CH, Bass AJ, Pretz J, Ahn J, Hricik T, Kilpivaara O, Wadleigh M, Busque L, Gilliland DG, Golub TR, Ebert BL, Levine RL. Rampal R, et al. Among authors: kilpivaara o. Blood. 2014 May 29;123(22):e123-33. doi: 10.1182/blood-2014-02-554634. Epub 2014 Apr 16. Blood. 2014. PMID: 24740812 Free PMC article.
Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms.
Shank K, Dunbar A, Koppikar P, Kleppe M, Teruya-Feldstein J, Csete I, Bhagwat N, Keller M, Kilpivaara O, Michor F, Levine RL, de Vargas Roditi L. Shank K, et al. Among authors: kilpivaara o. Haematologica. 2020 Mar;105(3):e91-e94. doi: 10.3324/haematol.2018.203729. Epub 2019 Aug 14. Haematologica. 2020. PMID: 31413098 Free PMC article. No abstract available.
Retrotransposon insertions can initiate colorectal cancer and are associated with poor survival.
Cajuso T, Sulo P, Tanskanen T, Katainen R, Taira A, Hänninen UA, Kondelin J, Forsström L, Välimäki N, Aavikko M, Kaasinen E, Ristimäki A, Koskensalo S, Lepistö A, Renkonen-Sinisalo L, Seppälä T, Kuopio T, Böhm J, Mecklin JP, Kilpivaara O, Pitkänen E, Palin K, Aaltonen LA. Cajuso T, et al. Among authors: kilpivaara o. Nat Commun. 2019 Sep 6;10(1):4022. doi: 10.1038/s41467-019-11770-0. Nat Commun. 2019. PMID: 31492840 Free PMC article.
52 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page